Implant Sciences Improves Its Quantum Sniffer Explosives Trace Detectors

• With New Detection Analysis and Reporting Software
• System Produces Usage Metrics, Legal Proof Tools, and Valuable Data for Security Regulators

Wilmington, MA - Implant Sciences Corporation (OTCQB: IMSC) (PINKSHEETS: IMSC), a high technology supplier of systems and sensors for homeland security markets, today announced it is enhancing its Quantum Sniffer(TM) QS-H150 and QS-B220 explosives trace detection devices with an advanced performance logging and reporting system. This new software package, offered as an accessory, will be available to the Company's current installed base of over 1,300 QS-H150 units as well as being offered in future QS-B220 and QS-H150 sales.

Running on a personal computer, the new software tool allows users to collect data from multiple Quantum Sniffers into a single data repository where it can be queried and organized to produce detailed reports. Information captured includes the time of scan, the system operator, substances detected (if any), and detailed analysis information for each positive detection.


The reports created by this system are of critical importance to government regulators who require metrics on detection equipment used for air cargo screening and at border and security checkpoints. The ability to precisely track usage also assists security administrators in optimizing system deployments as well as allowing the implementation of pay-per-scan compensation for security services. A detailed scan report is also provided that may be used as evidence submitted to court if and when scans result in legal proceedings.

"These new reporting capabilities significantly improve the value proposition and competitiveness of our QS-H150 and QS-B220 explosives trace detection equipment. Current and prospective customers have responded very positively to this product upgrade. We believe the logging and reporting capabilities will quickly lead to additional sales from both current and future customers," stated Implant Sciences CEO Glenn D. Bolduc.

Source : Implant Sciences Corp.